Pharmaceutical Industry in China: Jsbmarketresearch

Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies

Released On 23rd September 2015

Pharmaceutical Industry China – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. Pharmaceutical Industry China report is supported by over 199 tables & figures within 153 pages.

The Chinese biopharmaceutical market is presented as follows:

• By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)

• By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:

• Company financials, sales & revenue figures – historical to Q2•2013

• China GDP, economic growth, export (bulk drug, formulations) figures

• Indian health expenditure as a function of GDP

• Growth change figures of emerging and developing countries (India, Russia, China, Brazil)

• Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)

• Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:

• Key strengths, weaknesses and threats influencing leading player position within the market

• Top Five Contract Pharmaceutical Export Markets of China

• Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)

• Multinational penetration into the Chinese Pharma Market

• Comprehensive product portfolios, R&D activity and pipeline therapeutics

• M&A activity and future strategies of top Chinese pharmacos...